The risks behind Dengvaxia recommendation

The Lancet Infectious Diseases

Volumn 16, Issue 8, 2016, Pages 882-883

  Aguiar, Maíra ^a,b   Stollenwerk, Nico ^a   Halstead, Scott B ^c  

^a Universidade de Lisboa   (Portugal)

^b FUNDAÇÃO EZEQUIEL DIAS   (Brazil)

^c Uniformed Services University of the Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; DENGVAXIA; UNCLASSIFIED DRUG; VACCINE;

DENGUE; DENGUE VIRUS; ENDEMIC DISEASE; FATALITY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFECTION RISK; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SEROPREVALENCE; SEROTYPE; VACCINATION; WORLD HEALTH ORGANIZATION; RISK;

DENGUE; DENGUE VACCINES; HUMANS; RISK; VACCINE POTENCY;

EID: 84990026547     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30168-2     Document Type: Note

References (7)

1. 1 Brady, OJ, Gething, PW, Bhatt, S, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis, 6, 2012, e1760.
2. 2 Bhatt, S, Gething, PW, Brady, OJ, et al. The global distribution and burden of dengue. Nature 496 (2013), 504–507.
3. 3 Villar, L, Dayan, GH, Arredondo-Garcia, JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. New Engl J Med 372 (2015), 113–123.
4. 4 Capeding, MR, Tran, NH, Hadinegoro, SRS, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384 (2014), 1358–1365.
5. 5 Halstead, SB, Russell, PK, Protective and immunological behavior of yellow fever dengue chimeric vaccine. Vaccine 34 (2016), 1643–1647.
6. 6 Hadinegoro, SR, Arredondo-Garcia, JL, Capeding, MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373 (2015), 1195–1206.
7. 7 Flasche, S, Jit, M, Rodriguez-Barraquer, I, et al. Comparative modelling of dengue vaccine public health impact (CMDVI). http://www.who.int/immunization/sage/meetings/2016/april/presentations_background_docs/en/ (accessed May 7, 2016).